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Abstract 8 
Oral administration of drugs is one of the most patient-friendly drug delivery routes. However, drug 9 
bioavailability via the oral route remains poor due to the harsh gastrointestinal environment. In recent 10 
years, many nanocarriers have been designed to overcome this limitation. Among those, chitosan 11 
nanoparticles (ChNPs) have proved to be quite a popular choice. Here, we highlight the use of 12 
fluorescein isothiocyanate-tagged ChNPs (FITC@ChNPs) as an invaluable tool to monitor the fate 13 
of ChNPs encapsulating oral drugs, leading to an in-depth understanding of drug biodistribution and, 14 




Use of Chitosan Nanoparticles in Oral Drug Delivery 17 
Oral administration of drugs offers several benefits over other systemic drug delivery routes. 18 
Generally, the oral route is considered to be convenient, relatively safe and economically efficient. 19 
Additionally, this route often leads to improved patient compliance and lifestyle when compared to 20 
other delivery routes such as intravenous (IV) injection, which may present dermal pain and 21 
discomfort [1]. However, many peptide drugs and anti-cancer agents show several challenges upon 22 
oral administration, due to the low water solubility, unsuitable transport across the gastrointestinal 23 
(GI) mucosa, enzymatic degradation, or low pH deactivation. Moreover, the presence of tight 24 
junctions (TJs) and efflux pumps (such as P-glycoprotein) on enterocytes prevent both the 25 
paracellular and transcellular transports of any drugs. As a result, a suitable concentration of the drug 26 
in the blood stream, and in turn a suitable level of bioavailability, is not achieved [2,3]. In this context, 27 
many nanocarriers have been developed with the aim of improving the bioavailability of orally 28 
administered drugs. Among these, chitosan nanoparticles (ChNPs) have been extensively employed. 29 
as oral drug delivery systems as these can protect the encapsulated drug from GI degradation and 30 
promote its absorption across the GI mucosa [4]. The ChNPs provide researchers with the opportunity 31 
to functionalise their surface to obtain longer circulating and/or targeted delivery systems [4]. 32 
However, possessing a tool that enables researchers to monitor the fate of drug loaded ChNPs allows 33 
an in-depth understanding of the biodistribution of these ChNPs and drives better designs of NPs, 34 
which in turn enable improvements of the oral bioavailability of drugs. Here, we highlight the 35 
usefulness of fluorescein isothiocyanate-tagged ChNPs (FITC@ChNPs) as a tool to track the fate of 36 
ChNPs and monitor drug biodistribution and bioavailability.  37 
Chitosan is a glucosamine-based biopolymer, which is formed from naturally occurring chitin 38 
and characterized by a multitude of biological and pharmacological features, including wound 39 
healing, antioxidant and antibacterial properties, biodegradability, and biocompatibility [5]. It is 40 
produced by incomplete alkaline deacetylation of chitin, leading to enhanced water solubility under 41 
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acidic conditions. The aqueous solubility is due to the protonation of the free primary amino groups 42 
(pKa of the resulting -NH3+ = ~ 6.5) when chitosan is dissolved in weakly acidic solutions [5]. This 43 
behaviour also accounts for the mucoadhesive properties of chitosan: electrostatic bonds are 44 
established between the protonated amino groups and the negatively charged sialic acid anions of 45 
mucin glycoproteins, lining the mucous membrane of internal organs. 46 
Chitosan is used in a variety of applications, for instance in the production of drug nano 47 
vehicles, including micelles, and NPs [5]. The mucoadhesive property is valuable in achieving 48 
acceptable oral bioavailability since it allows ChNPs to adhere to the GI mucosa, increasing cellular 49 
absorption through adsorptive endocytosis and decreasing the required drug dosing frequency [6]. 50 
Moreover, the protonated amino groups can open TJs between epithelial cells, enhancing the 51 
paracellular transport of drugs [7]. However, this property is limited to the duodenum where the pH 52 
(6 - 7) is close to the pKa of chitosan [7]. In other pH ranges, chitosan loses its mucoadhesive 53 
properties and dissolves out [8]. To circumvent this, modifications of chitosan structure are needed. 54 
The presence of functional groups allows the chemical modification of chitosan with a variety of 55 
biomolecules such as methylcellulose phthalate (HPMCP) [1], thiol groups [9], methyl groups [10], 56 
and fluorescent molecules including FITC [11]. Such modifications increase the solubility and 57 
mucoadhesivity of chitosan, protect it from gastric dissolution [4], and allow ChNPs tracking across 58 
the GI tract using a fluorimeter. 59 
ChNPs are nanosized colloids that can be easily produced in aqueous media by simple 60 
methods such as ionic gelation [12]. Owing to their size, ChNPs have been shown to be able to cross 61 
biological membranes, such as the intestinal epithelium, yielding a high drug accumulation at the 62 
target site. Moreover, they preserve the enclosed therapeutic agent from degradation, increasing its 63 
bioavailability and, in turn, altering its pharmacokinetics [12]. The use of ChNPs loaded with drugs 64 
for oral use in clinical trials is desirable as it could lead to significant improvements over conventional 65 
drug delivery for diabetes management or the treatment of site-specific tumours. 66 
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Fluorescein Isothiocyanate-labelled Chitosan Nanoparticles 67 
ChNPs conjugated with fluorescent dyes are extensively used in biomedical applications such 68 
as cellular uptake studies and cellular imaging where owing to the added fluorescent feature, the 69 
intracellular and extracellular route of ChNPs can be efficiently tracked [13]. Nonetheless, the use of 70 
fluorescent NPs can pose several challenges. For instance, nonspecific detection can occur if the 71 
fluorophore is physically adsorbed on the surface of NPs. If the fluorophore is covalently conjugated 72 
to the drug delivery vehicle, its dissociation can be impeded during cellular uptake experiments or 73 
storage [13]. Several fluorophores such as lissamine-rhodamine and Cy5.5 have been conjugated to 74 
chitosan backbone so to allow the in vitro tracking of ChNPs. However, most of these organic 75 
fluorescent dyes show several limitations such as photobleaching, low signal intensity, toxicity, and 76 
poor solubility in water [11]. 77 
The conjugation of chitosan to FITC yields FITC@Ch and relies on a thiourea linkage, formed 78 
between the isothiocyanate group (R-N=C=S) on FITC and the primary amine groups (-NH2) on 79 
chitosan (Figure 1a). The conjugation reaction prevents the dissociation of the fluorescent probe, 80 
helping with quantification and tracking of the NPs [14]. The use of FITC presents several 81 
advantages, including the ease of conjugation to chitosan, solubility in water, photostability, good 82 
biocompatibility along with intense and stable fluorescence emission [11] that allows easy detection 83 
of small NPs. Furthermore, the properties of ChNPs are not compromised by the presence of FITC 84 
and FITC@ChNPs are widely reported in the literature to track and investigate biodistribution of 85 
ChNPs in the GI tract [14] as these can be easily and rapidly quantified by fluorimetry (Figure 1b). 86 
However, the major challenge in using FITC@ChNPs concerns the purity of the conjugates since a 87 
very low purity of FITC@Ch can lead to a misinterpretation of results.  Moreover, quantification of 88 
FITC@ChNPs by fluorimetry is only possible if a suitably accurate and sensitive method is developed 89 
[13]. 90 
FITC@ChNPs to increase bioavailability and biodistribution of various oral payloads 91 
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Investigations involving FITC@ChNPs can help find a suitable GI biodistribution of ChNPs, 92 
in turn increasing drug bioavailability (Figure 1b). Below we discuss recent key in vitro, ex vivo and 93 
in vivo studies involving FITC@ChNPs that aimed at enhancing the oral bioavailability of drugs.  94 
Protein payloads 95 
Protein drugs and vaccines play key roles in treating or managing numerous diseases, but upon 96 
oral administration they face several limitations including degradation by proteolytic enzymes and 97 
poor GI permeability [4]. For instance, insulin is a peptide hormone commonly used in diabetes 98 
management, but has poor patient compliance due to the requirement of daily subcutaneous injections 99 
[1]. To increase insulin oral bioavailability and biodistribution, several investigations have been 100 
performed employing insulin loaded on FITC@ChNPs. In a study conducted by Makhlof et al. [14], 101 
rats were fed with insulin loaded FITC@ChNPs cross-linked with HPMCP, a pH-sensitive polymer 102 
widely used to coat enteric capsules, protecting the encapsulated drug from gastric degradation [1]. 103 
FITC allowed the visualization of drug loaded NPs in the intestinal mucosa. A stronger fluorescence 104 
in the GI mucosa was noticed for rats treated with FITC@ChNPs cross-linked with HPMCP 105 
compared to the control (FITC@ChNPs) leading to the conclusion that cross-linking with HPMCP 106 
increased mucoadhesion and penetration of the insulin-loaded NPs through the intestine, in turn 107 
improving the peroral delivery of insulin. Cross-sections of the intestinal mucosa were further 108 
analysed by confocal microscopy and an interaction of NPs with the membrane was revealed, 109 
meaning that NPs were not trapped in the gel layer [14]. He et al. [1] evaluated the impact that the 110 
size of ChNPs has on the transport and absorption of the loaded insulin in Caco-2 cell monolayers 111 
(human intestinal cell line widely employed to investigate the ability of drug loaded NPs to cross the 112 
GI epithelium). This experiment was performed by labelling ChNPs with FITC so as to observe in 113 
real time the behaviour of the resulting NPs. Results showed that smaller NPs (45 nm) surmounted 114 
the epithelial barrier faster than larger ones (115 nm), as shown by the stronger fluorescent intensity 115 
given by the treatment with small FITC@ChNPs. Confocal images illustrated that the small NPs 116 
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induced a transient and reversible opening of TJs between enterocytes, increasing the concentration 117 
of the released insulin at the site of absorption, which is a desirable effect in targeted drug delivery 118 
[1].Another recent work employed FITC to assess the mucoadhesive properties and biodistribution 119 
of thiolated ChNPs for the oral delivery of insulin [9]. In vivo biodistribution studies were performed 120 
after oral administration of insulin loaded thiolated FITC@ChNPs to rats. A fluorescent layer was 121 
noticed above the microvilli of the GI mucosa, suggesting a suitable biodistribution of orally delivered 122 
insulin loaded FITC@ChNPs because of the enhanced mucoadhesivity conferred by the thiol groups 123 
on chitosan [9]. Moreover, cellular uptake of thiolated ChNPs was assessed in Caco-2 cells by means 124 
of FITC’s fluorescence intensity which showed that thiolated ChNPs were efficiently engulfed by 125 
cells. 126 
Vaccine studies have also used FITC labelled ChNPs to gain insights on the biodistribution 127 
profiles. For example, Liu et al. [15] employed FITC to label oleoyl-carboxymethyl Ch (CmCh) and 128 
generate NPs that acted as oral protein carriers of a bacterial antigen (extracellular products of 129 
Aeromonas hydrophila) so to stimulate an immune response. Carps were fed with the fluorescent 130 
NPs, the biodistribution of which was observed in vivo under the fluorescent microscope. A strong 131 
fluorescence given by FITC was detected in the mucous layer of the gut indicating successful 132 
mucoadhesion and permeation of the vaccine loaded CmChNPs [15]. 133 
Polysaccharide payloads 134 
Low molecular weight heparin, such as enoxaparin, is an anionic polysaccharide widely used 135 
as an anticoagulant. However, it cannot be orally administered due to its poor penetration through the 136 
GI epithelium [4]. Bagre et al. [8] tested the intestinal uptake of enoxaparin loaded in ChNPs coated 137 
with sodium alginate. FITC was employed as a fluorescent marker to track the fate of NPs upon oral 138 
administration to rats. The small intestine was extracted, and a stronger green fluorescence intensity 139 
was observed compared to uncoated NPs, suggesting that the sodium alginate coating increased the 140 
intestinal uptake of NPs. Therefore, the presence of FITC helped to conclude that the alginate coated 141 
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ChNPs are an adequate carrier for the delivery of enoxaparin through the intestinal epithelium and 142 
enhances the oral bioavailability of this drug. In another study, Fan et al. [16] employed FITC to 143 
study the in vivo intestinal mucoadhesion of enoxaparin loaded in ChNPs modified with thiol groups 144 
and HPMCP. Following oral administration to rats, confocal images showed a strong green 145 
fluorescence in the small intestine indicating stronger mucoadhesion compared to unmodified NPs. 146 
Chemotherapeutic drugs 147 
Chemotherapeutic drugs generally show low bioavailability upon oral administration. In this 148 
section, we discuss studies in which the use of FITC has assisted in the generation of chitosan-based 149 
nano vectors that can address this issue. Doxorubicin (Dox) is a drug widely used to treat breast, 150 
bladder and other cancers, and is normally IV administrated [17]. The oral bioavailability of Dox is 151 
limited by the efflux transporter P-glycoprotein which recognizes Dox as substrate, limiting its 152 
cellular uptake [17]. Yuan et al. [18] employed FITC to track the transport of Dox loaded chitosan 153 
micelles modified with stearic acid, across a monolayer of Caco-2 cells. Tracking the fluorescence 154 
intensity showed that micelles could cross the GI epithelium by micropinocytosis, suggesting that 155 
encapsulating Dox in such micelles can help overcome P-glycoprotein-mediated efflux processes and 156 
thus increase its bioavailability [18]. In another study, a polyelectrolyte complex nanocarrier, made 157 
of chitosan and FITC@CmCh NPs, was employed to deliver Dox to the GI mucosa in rats [10]. FITC 158 
allowed for the examination of the intestinal mucoadhesion of NPs ex vivo and a high fluorescence 159 
intensity was found through the entire small intestine indicating suitable drug loaded NPs 160 
biodistribution [10]. 161 
Curcumin is a polyphenolic compound with several pharmacologic properties, especially 162 
anticancer effects against colon cancer [19]. However, upon oral administration, it is characterized 163 
by poor bioavailability due to the low water solubility and cellular uptake [4]. Khatik et al. [20] coated 164 
the surface of curcumin loaded FITC@ChNPs with a pH sensible polymer Eudragit S 100 (Eds) so 165 
to direct NPs to the colon and avoid gastric degradation. A stronger fluorescence was detected in the 166 
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colon of rats fed with Eds coated NPs compared to uncoated NPs, indicating successful targeting and 167 
uptake of Eds coated curcumin loaded NPs by the colon [20]. 168 
Concluding remarks 169 
Above, we highlight the recent in vivo, ex vivo and in vitro studies that employed 170 
FITC@ChNPs to study factors involved in bioavailability and uptake of different payloads delivered 171 
orally. Labelling of drug-loaded NPs with FITC allows for tracking and studying them in vitro and 172 
in vivo in real-time after oral administration. Hence, FITC@ChNPs represent a versatile tool in the 173 
drug delivery arsenal as they can be successfully employed to monitor the fate of ChNPs, and in turn 174 
of the drug, in clinical investigations. 175 
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FIGURE LEGEND 221 
Figure 1. (a) The formation of fluorescein isothiocyanate-labelled chitosan nanoparticles 222 
(FITC@ChNPs). Chitosan is tagged with fluorescein isothiocyanate (FITC) via a substitution 223 
reaction, forming FITC-labelled chitosan (FITC@Ch), which contains a thiourea bond (shown in 224 
red). FITC@Ch is then formulated into FITC@ChNPs and loaded with the drug of choice. (b) The 225 
oral administration of drug loaded FITC@ChNPs allows to assess the drug bioavailability over 226 
the intestinal epithelium. FITC@ChNPs are orally administered to rats and following ingestion, 227 
detected in the intestinal epithelium by means of fluorimetry. Owing to chitosan’s mucoadhesion 228 
properties, ChNPs can cross the intestinal barrier so that the cargo is released in the blood stream, 229 
increasing its bioavailability.  230 
